501 related articles for article (PubMed ID: 18849173)
1. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus.
González-Ortiz M; Guerrero-Romero JF; Violante-Ortiz R; Wacher-Rodarte N; Martínez-Abundis E; Aguilar-Salinas C; Islas-Andrade S; Arechavaleta-Granell R; González-Canudas J; Rodríguez-Morán M; Zavala-Suárez E; Ramos-Zavala MG; Metha R; Revilla-Monsalve C; Beltrán-Jaramillo TJ
J Diabetes Complications; 2009; 23(6):376-9. PubMed ID: 18849173
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and safety of glimepiride plus metformin in a single presentation, as combined therapy, in patients with type 2 diabetes mellitus and secondary failure to glibenclamide, as monotherapy].
González-Ortiz M; Martínez-Abundis E;
Rev Invest Clin; 2004; 56(3):327-33. PubMed ID: 15612515
[TBL] [Abstract][Full Text] [Related]
3. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy.
Ferrannini E; Fonseca V; Zinman B; Matthews D; Ahrén B; Byiers S; Shao Q; Dejager S
Diabetes Obes Metab; 2009 Feb; 11(2):157-66. PubMed ID: 19125777
[TBL] [Abstract][Full Text] [Related]
4. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
Umpierrez G; Issa M; Vlajnic A
Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.
Hermansen K; Kipnes M; Luo E; Fanurik D; Khatami H; Stein P;
Diabetes Obes Metab; 2007 Sep; 9(5):733-45. PubMed ID: 17593236
[TBL] [Abstract][Full Text] [Related]
6. An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin.
Barnett AH; Dreyer M; Lange P; Serdarevic-Pehar M
Diabetes Care; 2006 Aug; 29(8):1818-25. PubMed ID: 16873786
[TBL] [Abstract][Full Text] [Related]
7. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
[TBL] [Abstract][Full Text] [Related]
8. Comparison of glargine insulin versus rosiglitazone addition in poorly controlled type 2 diabetic patients on metformin plus sulfonylurea.
Triplitt C; Glass L; Miyazaki Y; Wajcberg E; Gastaldelli A; De Filippis E; Cersosimo E; DeFronzo RA
Diabetes Care; 2006 Nov; 29(11):2371-7. PubMed ID: 17065670
[TBL] [Abstract][Full Text] [Related]
9. Results of a randomized, double-blind, placebo-controlled study administering glimepiride to patients with type 2 diabetes mellitus inadequately controlled with rosiglitazone monotherapy.
McCluskey D; Touger MS; Melis R; Schleusener DS; McCluskey D
Clin Ther; 2004 Nov; 26(11):1783-90. PubMed ID: 15639690
[TBL] [Abstract][Full Text] [Related]
10. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
Massi-Benedetti M; Herz M; Pfeiffer C
Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
[TBL] [Abstract][Full Text] [Related]
11. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
12. Canagliflozin provides durable glycemic improvements and body weight reduction over 104 weeks versus glimepiride in patients with type 2 diabetes on metformin: a randomized, double-blind, phase 3 study.
Leiter LA; Yoon KH; Arias P; Langslet G; Xie J; Balis DA; Millington D; Vercruysse F; Canovatchel W; Meininger G
Diabetes Care; 2015 Mar; 38(3):355-64. PubMed ID: 25205142
[TBL] [Abstract][Full Text] [Related]
13. Patient-reported outcomes in patients with type 2 diabetes treated with liraglutide or glimepiride, both as add-on to metformin.
Hermansen K; Kolotkin RL; Hammer M; Zdravkovic M; Matthews D
Prim Care Diabetes; 2010 Jul; 4(2):113-7. PubMed ID: 20444662
[TBL] [Abstract][Full Text] [Related]
14. Evaluation, efficacy and tolerability of GlucoNovax tablet in type 2 diabetic patients.
Ali Z; Daniyal M; S I I; Usmanghani K; Naveed S
Pak J Pharm Sci; 2016 Jul; 29(4 Suppl):1443-9. PubMed ID: 27592478
[TBL] [Abstract][Full Text] [Related]
15. Probable hypoglycemic adverse drug reaction associated with prickly pear cactus, glipizide, and metformin in a patient with type 2 diabetes mellitus.
Sobieraj DM; Freyer CW
Ann Pharmacother; 2010; 44(7-8):1334-7. PubMed ID: 20516361
[TBL] [Abstract][Full Text] [Related]
16. Glibenclamide-related excess in total and cardiovascular mortality risks: data from large Ukrainian observational cohort study.
Khalangot M; Tronko M; Kravchenko V; Kovtun V
Diabetes Res Clin Pract; 2009 Dec; 86(3):247-53. PubMed ID: 19796836
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia.
Holstein A; Plaschke A; Hammer C; Egberts EH
Eur J Clin Pharmacol; 2003 Jun; 59(2):91-7. PubMed ID: 12698302
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of glimepiride/metformin sustained release once daily vs. glimepiride/metformin twice daily in patients with type 2 diabetes.
Hwang YC; Kang M; Ahn CW; Park JS; Baik SH; Chung DJ; Jang HC; Kim KA; Lee IK; Min KW; Nam M; Park TS; Son SM; Sung YA; Woo JT; Park KS; Lee MK
Int J Clin Pract; 2013 Mar; 67(3):236-43. PubMed ID: 23336668
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic basis for the safety of glimepiride in risk groups of NIDDM patients.
Rosenkranz B
Horm Metab Res; 1996 Sep; 28(9):434-9. PubMed ID: 8911979
[TBL] [Abstract][Full Text] [Related]
20. Improved glycaemic control with metformin-glibenclamide combined tablet therapy (Glucovance) in Type 2 diabetic patients inadequately controlled on metformin.
Marre M; Howlett H; Lehert P; Allavoine T
Diabet Med; 2002 Aug; 19(8):673-80. PubMed ID: 12147149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
